Court ruling likely to boost spirits and ultimately transactions in the sector
Source
Author: unknown
Healthcare M&A: Titans on spree as regulatory crackdown falls flat [Mergers & Acquisitions]
Related Posts
Novartis Doubles Down on Early-Stage M&A Strategy as Near-Launch Assets Become Scarce
null Novartis is reinforcing its commitment to acquiring early-stage pipeline assets and clinical-stage candidates, even as the pharmaceutical giant faces intensifying competition for late-stage drug...
Mubadala Exits Arcadia Consumer Healthcare as Bansk Group Assumes Full Control in Continuation Vehicle
Mubadala Capital has sold its minority stake in Arcadia Consumer Healthcare to funds managed by Bansk Group, marking the end of a four-year partnership that tripled the platform's revenue and...
Revolution Medicines Stock Plunges 20% as Merck Ends $28-32 Billion Acquisition Talks Over Valuation Rift
Merck & Co. has terminated acquisition discussions with Revolution Medicines after failing to agree on price for a potential $28-32 billion deal, triggering a 20% drop in Revolution's shares and...
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
BioCryst Pharmaceuticals Inc. (NasdaqGS: BCRX) completed its acquisition of Astria Therapeutics Inc. (NasdaqGM: ATXS) from a group of shareholders on January 23, 2026, in a deal valued at $700...